[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"saliva-collection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:saliva-collection":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,66],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100648424","phase-4-the-association-between-bilateral-intermediate-cervical-plexus-block-and-salivary-biomarkers-of-surgical-stress-response-following-total-thyroidectomy-100648424",false,"NCT07721818","The Association Between Bilateral Intermediate Cervical Plexus Block and Salivary Biomarkers of Surgical Stress Response Following Total Thyroidectomy","Inclusion Criteria:\n\n* ASA I or ASA II\n* euthyroid status\n* signed informed consent\n\nExclusion Criteria:\n\n* patients who refuse to sign the informed consent form\n* infection at the block injection site\n* hypersensitivity or contraindications to the medication used in the study\n* hypo\u002Fhyperthyroidism at the time of surgery\n* presence of substernal goiter\n* additional surgical interventions during the procedure\n* history of previous neck surgery or radiation\n* coagulopathy\n* uncontroled respiratory disease\n* diabetes mellitus\n* autoimune disease\n* chronic corticosteroid therapy\n* smokers\n* pregnant women","ALL","18 Years",{"count":18,"type":19},48,"ESTIMATED","INTERVENTIONAL",[22],"PHASE4","The aim of this study is to evaluate how an ultrasound-guided bilateral intermediate cervical plexus block affects the surgical stress response in individuals undergoing total thyroidectomy. The primary objective is to quantify this physiological response through the analysis of specific stress and inflammatory biomarkers collected from the participants' saliva.\n\nThe clinical trial will encompass a total of 48 patients, randomized equally into two distinct cohorts of 24 participants each. The control group will undergo standard total intravenous anesthesia (TIVA), whereas the experimental group will receive the bilateral intermediate cervical plexus block in combination with the TIVA protocol.\n\nIt is hypothesized that integrating this regional nerve block with total intravenous anesthesia will significantly attenuate the surgical stress response, evidenced by a reduction in salivary biomarker concentration, compared to utilizing TIVA alone during thyroid surgery.\n\nValidating this hypothesis would offer robust scientific evidence to advocate for the routine integration of the bilateral intermediate cervical plexus block into standard anesthetic practices for total thyroidectomy. Ultimately, this approach aims to minimize perioperative stress and facilitate a more rapid postoperative recovery for patients.",[25,26,27,28],"Surgical Stress Response","Total Thyroidectomy","Saliva Collection","Cervical Plexus Block","NOT_YET_RECRUITING","2026-07-20",{"date":32,"type":33},"2026-07-23","ACTUAL",{"date":35,"type":19},"2026-08-01",{"date":37,"type":19},"2027-04",{"name":39,"class":40},"University Hospital Dubrava","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":65},"100648268","salivary-function-and-dental-changes-during-glp-1-therapy-100648268","NCT07720466","Salivary Function and Dental Changes During GLP-1 Therapy","Prospective Evaluation of Salivary Calcium Levels, Salivary Function, and Dental Hard Tissue Changes in Patients Receiving GLP-1 Receptor Agonist Therapy","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Body mass index (BMI) ≥27 kg\u002Fm².\n* Clinical decision by an endocrinologist to initiate semaglutide or tirzepatide therapy for obesity management.\n* No previous treatment with GLP-1 receptor agonists.\n* Willingness to participate and ability to provide written informed consent.\n* Willingness to attend both the baseline and 3-month follow-up visits.\n\nExclusion Criteria:\n\n* Previous use of any GLP-1 receptor agonist.\n* History of head and neck radiotherapy.\n* Sjögren syndrome or other systemic diseases affecting salivary gland function.\n* Chronic kidney disease.\n* Pregnancy or breastfeeding.\n* Use of medications known to markedly affect salivary secretion.\n* Active orthodontic treatment.\n* Severe dental erosion requiring restorative treatment at baseline.\n* Edentulism or the absence of anterior teeth required for dental hard tissue assessment.\n* Inability or unwillingness to comply with the study protocol or attend the 3-month follow-up visit.\n* History of eating disorders associated with recurrent self-induced vomiting (e.g., bulimia nervosa).\n* Medical conditions causing persistent vomiting or severe gastroesophageal disease unrelated to GLP-1 therapy.",{"count":49,"type":19},40,"OBSERVATIONAL","People who use glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide and tirzepatide, may experience changes in their oral health. Some people report dry mouth, changes in saliva, and increased wear of their teeth after starting these medicines. However, little is known about whether these medicines affect saliva and dental hard tissues.\n\nThe purpose of this study is to evaluate changes in salivary calcium levels, salivary function, and dental hard tissues in adults who begin treatment with semaglutide or tirzepatide for obesity.\n\nApproximately 40 participants will be enrolled before starting GLP-1 receptor agonist therapy. Oral examinations, standardized intraoral photographs, saliva samples, and body weight measurements will be obtained before treatment and again after three months. Saliva samples will be analyzed for calcium concentration, pH, and salivary flow rate. Dental hard tissue changes will be assessed using the Basic Erosive Wear Examination (BEWE) index.\n\nThe findings from this study may improve understanding of the effects of GLP-1 receptor agonists on oral health and help healthcare professionals identify and prevent possible dental complications during treatment.",[53,54,27,55],"Obesity","Dental Erosion","Saliva Altered","2026-07-17",{"date":58,"type":33},"2026-07-22",{"date":60,"type":19},"2026-08-17",{"date":62,"type":19},"2027-03-17",{"name":64,"class":40},"Bilecik Seyh Edebali Universitesi",1,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":74,"sex":15,"minAge":16,"maxAge":75,"enrollmentInfo":76,"targetDuration":78,"studyType":50,"phases":4,"briefSummary":79,"conditions":80,"keywords":85,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":4},"100639694","pilot-study-of-salivary-bile-acids-and-pepsin-as-predictive-biomarkers-of-reflux-disease-after-sleeve-gastrectomy-100639694","NCT07607067","Pilot Study of Salivary Bile Acids and Pepsin as Predictive Biomarkers of Reflux Disease After Sleeve Gastrectomy","Prospective Pilot Study of Salivary Bile Acids and Pepsin as Predictive Biomarkers of Reflux Disease and Esophageal Injury After Sleeve Gastrectomy","ABSORB","Inclusion Criteria:\n\n* Adults aged 18 years or older undergoing sleeve gastrectomy at a participating center.\n* Indication for obesity treatment with sleeve gastrectomy according to the 2022 ASMBS-IFSO consensus criteria, with a maximum body mass index (BMI) of 50 kg\u002Fm².\n* Approved for sleeve gastrectomy by the obesity multidisciplinary committee.\n* Ability and willingness to provide informed consent for biological sample collection and analysis.\n* Ability to understand and comply with scheduled follow-up visits.\n\nExclusion Criteria:\n\n* According to Lyon 2.0 criteria, participants with previous evidence of conclusive reflux disease, including Los Angeles grade B, C, or D esophagitis, peptic stricture, or Barrett's esophagus diagnosed before surgery.\n* Bariatric procedures other than sleeve gastrectomy, including Roux-en-Y gastric bypass or revisional bariatric surgery.\n* History of other preexisting esophageal diseases.\n* Previous esophageal surgery.\n* Active cholestatic hepatobiliary disease or treatment with bile acid sequestrants, ursodeoxycholic acid, or medications that significantly alter bile acid metabolism at the time of saliva sampling or within one month before sample collection.\n* Acute infection or systemic antibiotic treatment within four weeks before saliva sample collection.\n* Pregnancy or breastfeeding.",true,"65 Years",{"count":77,"type":19},60,"3 Years","The goal of this observational study is to learn whether bile acids and pepsin in saliva can help identify adults at higher risk of developing reflux-related esophageal disease after sleeve gastrectomy, including Los Angeles grade B-D erosive esophagitis and Barrett's esophagus. The study will include adults undergoing sleeve gastrectomy as part of their regular clinical care. Participants will be evaluated before and after surgery and will serve as their own comparison group over time.\n\nThe main questions it aims to answer are:\n\nAre saliva bile acids and pepsin linked to Los Angeles grade B-D erosive esophagitis or Barrett's esophagus after sleeve gastrectomy? How do saliva bile acids and pepsin change before and after sleeve gastrectomy? Can saliva bile acids and pepsin become useful biomarkers for detecting reflux-related esophageal disease after sleeve gastrectomy? Are saliva biomarker levels linked to reflux symptoms and endoscopy results after surgery?\n\nResearchers will compare saliva biomarker levels before and after surgery and between participants with and without reflux-related esophageal disease.\n\nParticipants will:\n\nProvide saliva samples before surgery and at 12 and 36 months after surgery Provide fasting and post-meal saliva samples Undergo routine postoperative clinical follow-up and upper gastrointestinal endoscopy Complete reflux symptom questionnaires during follow-up\n\nThe study will also explore whether saliva biomarkers could help select participants for follow-up endoscopy after sleeve gastrectomy.",[81,82,27,83,84],"Reflux Disease, Gastro-Esophageal","Sleeve Gastrectomy","Reflux Esophagitis (RE)","Barrett Esophagus",[86,87,88,89,84],"sleeve gastrectomy","bile acid reflux","salivary biomarkers","erosive esophagitis","2026-05-19",{"date":92,"type":33},"2026-05-26",{"date":94,"type":19},"2026-12",{"date":96,"type":19},"2029-12",{"name":98,"class":40},"Hospital de Mataró"]